Unknown

Dataset Information

0

A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli.


ABSTRACT: Monoclonal antibodies (mABs) are of great biopharmaceutical importance for the diagnosis and treatment of diseases. However, their production in mammalian expression hosts usually requires extensive production times and is expensive. Escherichia coli has become a new platform for production of functional small antibody fragment variants. In this study, we have used a rhamnose-inducible expression system that allows precise control of protein expression levels. The system was first evaluated for the cytoplasmic production of super folder green fluorescence protein (sfGFP) in various production platforms and then for the periplasmic production of the anti-HIV single-chain variable antibody fragment (scFv) of PGT135. Anti-HIV broadly neutralizing antibodies, like PGT135, have potential for clinical use to prevent HIV transmission, to promote immune responses and to eradicate infected cells. Different concentrations of L-rhamnose resulted in the controlled production of both sfGFP and scFv PGT135 antibody. In addition, by optimizing the culture conditions, the amount of scFv PGT135 antibody that was expressed soluble or as inclusions bodies could be modulated. The proteins were produced in batch bioreactors, with yields of 4.9 g/L for sfGFP and 0.8 g/L for scFv. The functionality of the purified antibodies was demonstrated by their ability to neutralize a panel of different HIV variants in vitro. We expect that this expression system will prove very useful for the development of a more cost-effective production process for proteins and antibody fragments in microbial cells.

SUBMITTER: Petrus MLC 

PROVIDER: S-EPMC6851033 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

A microbial expression system for high-level production of scFv HIV-neutralizing antibody fragments in Escherichia coli.

Petrus Marloes L C MLC   Kiefer Lukas A LA   Puri Pranav P   Heemskerk Evert E   Seaman Michael S MS   Barouch Dan H DH   Arias Sagrario S   van Wezel Gilles P GP   Havenga Menzo M  

Applied microbiology and biotechnology 20191022 21-22


Monoclonal antibodies (mABs) are of great biopharmaceutical importance for the diagnosis and treatment of diseases. However, their production in mammalian expression hosts usually requires extensive production times and is expensive. Escherichia coli has become a new platform for production of functional small antibody fragment variants. In this study, we have used a rhamnose-inducible expression system that allows precise control of protein expression levels. The system was first evaluated for  ...[more]

Similar Datasets

| S-EPMC4374706 | biostudies-literature
| S-EPMC10883104 | biostudies-literature
| S-EPMC2821263 | biostudies-literature
| S-EPMC7504322 | biostudies-literature
| S-EPMC4815333 | biostudies-literature
| S-EPMC5703365 | biostudies-literature
| S-EPMC4836414 | biostudies-other
| S-EPMC4222104 | biostudies-literature
| S-EPMC287326 | biostudies-other
| S-EPMC8057744 | biostudies-literature